Home › Funds › LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA › ABT
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA position in ABT
ABBOTT LABORATORIES · Health Care
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reported holding 1,530,620 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$151.3M, representing 1.40% of its reported portfolio and ranking #23 among its reported holdings. LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's ABT position evolved
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA first disclosed a stake in ABT in Q3 2023 at 1,765,277 shares (US$169.4M). The position peaked in Q2 2025 at 1,684,770 shares, worth US$229.1M. Across 13 filings, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA increased the stake 0 time(s), trimmed it 9 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 1,530,620 shares valued at US$151.3M — a reduction of -35,566 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.77M | $169.40M | New |
| Q4 2023 | 1.76M | $198.92M | Hold |
| Q1 2024 | 1.75M | $186.92M | Reduce |
| Q2 2024 | 1.74M | $179.04M | Hold |
| Q3 2024 | 1.73M | $201.59M | Reduce |
| Q4 2024 | 1.72M | $223.10M | Hold |
| Q1 2025 | 1.70M | $220.58M | Reduce |
| Q2 2025 | 1.68M | $229.15M | Reduce |
| Q3 2025 | 1.67M | $210.96M | Reduce |
| Q4 2025 | 1.65M | $178.30M | Reduce |
| Q1 2026 | 1.61M | $161.89M | Reduce |
| Q2 2026 | 1.57M | $142.12M | Reduce |
| Q3 2026 | 1.53M | $151.27M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 44.98M sh · $4.45B · Q3 2026
- Capital International Investors 35.46M sh · $3.51B · Q3 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Franklin Resources 20.44M sh · $2.36B · Q3 2026
- Deutsche Bank AG 17.69M sh · $1.75B · Q3 2026
- MFS Investment Management 14.93M sh · $1.48B · Q3 2026
More on LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
FAQ
How long has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA held ABT?
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's current position in ABT?
As of Q3 2026, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA holds 1.53M shares of ABT (ABBOTT LABORATORIES), valued at $151.27M, representing 1.40% of its reported portfolio and ranking #23.
Has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA been buying or selling ABT?
In the latest 13F filing (Q3 2026), LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reduced its position in ABT. The position peaked in Q2 2025 at 1.68M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.